Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Myocardial Perfusion Imaging | 48 | 2023 | 57 | 22.020 |
Why?
|
Tomography, Emission-Computed, Single-Photon | 43 | 2023 | 75 | 13.830 |
Why?
|
Coronary Artery Disease | 26 | 2023 | 125 | 13.580 |
Why?
|
Purines | 21 | 2020 | 34 | 9.720 |
Why?
|
Pyrazoles | 22 | 2020 | 50 | 9.540 |
Why?
|
Myocardial Ischemia | 14 | 2020 | 49 | 6.690 |
Why?
|
Kidney Failure, Chronic | 12 | 2023 | 159 | 5.880 |
Why?
|
Exercise Test | 23 | 2020 | 124 | 5.270 |
Why?
|
Myocardial Infarction | 14 | 2023 | 174 | 5.100 |
Why?
|
Thrombosis | 10 | 2022 | 59 | 4.700 |
Why?
|
Kidney Transplantation | 7 | 2023 | 126 | 4.310 |
Why?
|
Adenosine A2 Receptor Agonists | 10 | 2019 | 11 | 4.110 |
Why?
|
Prognosis | 34 | 2023 | 878 | 3.960 |
Why?
|
Atrial Fibrillation | 13 | 2022 | 180 | 3.890 |
Why?
|
Aminophylline | 9 | 2018 | 9 | 3.300 |
Why?
|
Heart Failure | 14 | 2022 | 206 | 3.200 |
Why?
|
Humans | 132 | 2023 | 29885 | 3.150 |
Why?
|
Middle Aged | 61 | 2022 | 9958 | 2.840 |
Why?
|
Heart Diseases | 5 | 2021 | 75 | 2.720 |
Why?
|
Renal Insufficiency, Chronic | 5 | 2021 | 97 | 2.690 |
Why?
|
Male | 74 | 2023 | 15870 | 2.650 |
Why?
|
Risk Assessment | 22 | 2021 | 685 | 2.590 |
Why?
|
Female | 75 | 2023 | 16473 | 2.570 |
Why?
|
Risk Factors | 34 | 2023 | 2466 | 2.290 |
Why?
|
Atrial Appendage | 8 | 2022 | 45 | 2.260 |
Why?
|
Liver Transplantation | 4 | 2021 | 79 | 2.250 |
Why?
|
Echocardiography, Transesophageal | 6 | 2019 | 46 | 2.230 |
Why?
|
Patient Selection | 7 | 2021 | 235 | 2.210 |
Why?
|
Retrospective Studies | 32 | 2023 | 3325 | 2.120 |
Why?
|
Cardiology | 9 | 2020 | 73 | 2.090 |
Why?
|
Aged | 48 | 2022 | 9620 | 2.060 |
Why?
|
Vasodilator Agents | 9 | 2018 | 33 | 2.010 |
Why?
|
Heart | 7 | 2023 | 92 | 1.940 |
Why?
|
Stroke Volume | 9 | 2022 | 59 | 1.920 |
Why?
|
Predictive Value of Tests | 17 | 2021 | 533 | 1.830 |
Why?
|
Electrocardiography | 6 | 2018 | 216 | 1.800 |
Why?
|
Coronary Angiography | 8 | 2023 | 91 | 1.750 |
Why?
|
Death, Sudden, Cardiac | 4 | 2015 | 20 | 1.700 |
Why?
|
Pulmonary Embolism | 5 | 2022 | 59 | 1.600 |
Why?
|
Heart Rate | 3 | 2017 | 148 | 1.590 |
Why?
|
Echocardiography | 9 | 2023 | 171 | 1.570 |
Why?
|
Reproducibility of Results | 15 | 2019 | 803 | 1.540 |
Why?
|
Natriuretic Peptide, Brain | 4 | 2021 | 11 | 1.490 |
Why?
|
Diagnostic Imaging | 3 | 2021 | 90 | 1.470 |
Why?
|
Prospective Studies | 19 | 2020 | 1837 | 1.460 |
Why?
|
Percutaneous Coronary Intervention | 4 | 2022 | 23 | 1.320 |
Why?
|
Mitral Valve | 3 | 2020 | 12 | 1.310 |
Why?
|
Sensitivity and Specificity | 12 | 2018 | 558 | 1.270 |
Why?
|
Nuclear Medicine | 5 | 2019 | 6 | 1.230 |
Why?
|
Ventricular Dysfunction, Left | 3 | 2022 | 42 | 1.210 |
Why?
|
Randomized Controlled Trials as Topic | 12 | 2022 | 348 | 1.190 |
Why?
|
Cardiovascular Diseases | 6 | 2021 | 411 | 1.180 |
Why?
|
Drug-Eluting Stents | 3 | 2022 | 11 | 1.160 |
Why?
|
Unnecessary Procedures | 3 | 2015 | 24 | 1.140 |
Why?
|
Heart-Assist Devices | 4 | 2019 | 22 | 1.120 |
Why?
|
Troponin I | 2 | 2017 | 11 | 1.120 |
Why?
|
Coronary Stenosis | 2 | 2018 | 14 | 1.120 |
Why?
|
Transcatheter Aortic Valve Replacement | 6 | 2023 | 27 | 1.120 |
Why?
|
Heart Valve Prosthesis Implantation | 4 | 2023 | 22 | 1.110 |
Why?
|
Multimodal Imaging | 3 | 2021 | 20 | 1.100 |
Why?
|
Ventricular Function, Left | 5 | 2020 | 49 | 1.060 |
Why?
|
Treatment Outcome | 27 | 2023 | 3557 | 1.040 |
Why?
|
Ventricular Dysfunction, Right | 3 | 2021 | 11 | 1.040 |
Why?
|
United States | 17 | 2023 | 2345 | 1.030 |
Why?
|
Biomarkers | 8 | 2021 | 703 | 0.970 |
Why?
|
Conservative Treatment | 2 | 2021 | 13 | 0.960 |
Why?
|
Heart Valve Diseases | 3 | 2020 | 23 | 0.960 |
Why?
|
Comorbidity | 9 | 2021 | 503 | 0.960 |
Why?
|
Angina Pectoris | 2 | 2023 | 18 | 0.950 |
Why?
|
Diarrhea | 3 | 2012 | 47 | 0.940 |
Why?
|
Heart Ventricles | 3 | 2021 | 169 | 0.940 |
Why?
|
Aortic Valve Stenosis | 5 | 2023 | 23 | 0.920 |
Why?
|
Incidence | 9 | 2020 | 761 | 0.910 |
Why?
|
Aortic Valve Insufficiency | 2 | 2023 | 9 | 0.900 |
Why?
|
Chicago | 10 | 2019 | 868 | 0.890 |
Why?
|
Insurance Coverage | 2 | 2020 | 13 | 0.850 |
Why?
|
Medicaid | 2 | 2020 | 37 | 0.830 |
Why?
|
Platelet Aggregation Inhibitors | 4 | 2022 | 50 | 0.820 |
Why?
|
Follow-Up Studies | 10 | 2019 | 1855 | 0.790 |
Why?
|
Medicare | 2 | 2019 | 123 | 0.790 |
Why?
|
Calcium | 3 | 2021 | 493 | 0.780 |
Why?
|
Hematoma | 1 | 2021 | 19 | 0.780 |
Why?
|
Cardiomyopathies | 3 | 2020 | 31 | 0.770 |
Why?
|
Coronary Vessels | 1 | 2021 | 46 | 0.760 |
Why?
|
Image Enhancement | 2 | 2018 | 57 | 0.760 |
Why?
|
Cohort Studies | 10 | 2020 | 1954 | 0.760 |
Why?
|
Double-Blind Method | 7 | 2016 | 522 | 0.760 |
Why?
|
Adult | 15 | 2020 | 8773 | 0.750 |
Why?
|
Survival Rate | 6 | 2017 | 377 | 0.750 |
Why?
|
Antihypertensive Agents | 2 | 2022 | 85 | 0.740 |
Why?
|
Diltiazem | 1 | 2020 | 6 | 0.740 |
Why?
|
Atrioventricular Node | 1 | 2020 | 6 | 0.740 |
Why?
|
Primary Health Care | 2 | 2013 | 95 | 0.740 |
Why?
|
Hyperkalemia | 1 | 2020 | 7 | 0.730 |
Why?
|
Severity of Illness Index | 8 | 2020 | 1126 | 0.730 |
Why?
|
Bradycardia | 1 | 2020 | 29 | 0.720 |
Why?
|
Patient Protection and Affordable Care Act | 1 | 2020 | 22 | 0.710 |
Why?
|
Critical Pathways | 2 | 2017 | 22 | 0.710 |
Why?
|
Decision Support Systems, Clinical | 1 | 2019 | 10 | 0.700 |
Why?
|
Prasugrel Hydrochloride | 1 | 2019 | 2 | 0.700 |
Why?
|
Multidetector Computed Tomography | 2 | 2021 | 6 | 0.700 |
Why?
|
Tissue Survival | 1 | 2019 | 1 | 0.700 |
Why?
|
Defibrillators, Implantable | 1 | 2020 | 33 | 0.700 |
Why?
|
Calcinosis | 1 | 2020 | 48 | 0.700 |
Why?
|
Acute Coronary Syndrome | 1 | 2019 | 15 | 0.690 |
Why?
|
Syncope | 1 | 2019 | 8 | 0.690 |
Why?
|
Bundle-Branch Block | 1 | 2019 | 15 | 0.680 |
Why?
|
Esophageal and Gastric Varices | 1 | 2019 | 2 | 0.670 |
Why?
|
Aged, 80 and over | 13 | 2022 | 4932 | 0.670 |
Why?
|
Echocardiography, Doppler | 2 | 2016 | 22 | 0.660 |
Why?
|
Decision Support Techniques | 1 | 2019 | 51 | 0.660 |
Why?
|
Cardiac Tamponade | 1 | 2018 | 3 | 0.660 |
Why?
|
Oximetry | 1 | 2018 | 12 | 0.660 |
Why?
|
Artificial Intelligence | 1 | 2019 | 22 | 0.660 |
Why?
|
Arrhythmias, Cardiac | 1 | 2020 | 152 | 0.660 |
Why?
|
Machine Learning | 1 | 2019 | 54 | 0.650 |
Why?
|
Pericardial Effusion | 1 | 2018 | 4 | 0.640 |
Why?
|
Myocardium | 2 | 2019 | 143 | 0.640 |
Why?
|
Aortic Valve | 5 | 2023 | 21 | 0.630 |
Why?
|
Contrast Media | 1 | 2018 | 125 | 0.620 |
Why?
|
Radiopharmaceuticals | 4 | 2020 | 53 | 0.590 |
Why?
|
Cardiac Imaging Techniques | 1 | 2017 | 5 | 0.590 |
Why?
|
Cardiac-Gated Single-Photon Emission Computer-Assisted Tomography | 1 | 2017 | 1 | 0.590 |
Why?
|
Medical Overuse | 1 | 2017 | 6 | 0.580 |
Why?
|
Preoperative Care | 2 | 2015 | 135 | 0.580 |
Why?
|
Accreditation | 1 | 2016 | 16 | 0.570 |
Why?
|
Purinergic P1 Receptor Antagonists | 2 | 2013 | 2 | 0.560 |
Why?
|
Hospitalization | 6 | 2021 | 318 | 0.550 |
Why?
|
Prevalence | 7 | 2023 | 494 | 0.550 |
Why?
|
Radiation Exposure | 1 | 2016 | 7 | 0.550 |
Why?
|
Hemodynamics | 1 | 2016 | 89 | 0.550 |
Why?
|
Neoplasms, Radiation-Induced | 1 | 2016 | 16 | 0.540 |
Why?
|
Guideline Adherence | 4 | 2019 | 67 | 0.540 |
Why?
|
Diet, Sodium-Restricted | 1 | 2016 | 6 | 0.540 |
Why?
|
Cardio-Renal Syndrome | 1 | 2015 | 1 | 0.540 |
Why?
|
Sexism | 1 | 2015 | 8 | 0.530 |
Why?
|
Hospital Mortality | 5 | 2021 | 140 | 0.520 |
Why?
|
Registries | 4 | 2023 | 191 | 0.520 |
Why?
|
Insurance Carriers | 1 | 2015 | 2 | 0.520 |
Why?
|
Adenosine | 1 | 2015 | 12 | 0.520 |
Why?
|
Technetium | 1 | 2015 | 6 | 0.510 |
Why?
|
Cardiotonic Agents | 4 | 2018 | 12 | 0.510 |
Why?
|
Social Class | 1 | 2015 | 65 | 0.500 |
Why?
|
Perfusion | 4 | 2023 | 21 | 0.500 |
Why?
|
End Stage Liver Disease | 1 | 2014 | 12 | 0.500 |
Why?
|
Physicians' Offices | 2 | 2013 | 7 | 0.490 |
Why?
|
Myocardial Revascularization | 4 | 2020 | 18 | 0.490 |
Why?
|
Rheumatic Heart Disease | 1 | 2014 | 1 | 0.480 |
Why?
|
Hyperemia | 1 | 2014 | 2 | 0.480 |
Why?
|
Echocardiography, Stress | 1 | 2014 | 1 | 0.470 |
Why?
|
Thrombophilia | 1 | 2014 | 7 | 0.470 |
Why?
|
Emigrants and Immigrants | 1 | 2014 | 21 | 0.470 |
Why?
|
Hyperthyroidism | 1 | 2014 | 11 | 0.470 |
Why?
|
Thromboembolism | 1 | 2014 | 19 | 0.470 |
Why?
|
Cross-Sectional Studies | 8 | 2020 | 970 | 0.460 |
Why?
|
Heart Failure, Systolic | 1 | 2013 | 3 | 0.460 |
Why?
|
Technetium Tc 99m Sestamibi | 3 | 2019 | 9 | 0.450 |
Why?
|
Urban Population | 1 | 2014 | 143 | 0.440 |
Why?
|
Women's Health | 1 | 2015 | 247 | 0.440 |
Why?
|
Pulmonary Disease, Chronic Obstructive | 1 | 2014 | 43 | 0.440 |
Why?
|
Kaplan-Meier Estimate | 4 | 2018 | 177 | 0.440 |
Why?
|
Renal Dialysis | 3 | 2019 | 111 | 0.440 |
Why?
|
Diabetes Complications | 1 | 2013 | 64 | 0.440 |
Why?
|
Lung | 1 | 2014 | 158 | 0.430 |
Why?
|
Dizziness | 1 | 2012 | 20 | 0.430 |
Why?
|
Physicians | 1 | 2014 | 117 | 0.420 |
Why?
|
Angina, Unstable | 2 | 2002 | 11 | 0.420 |
Why?
|
Abdominal Pain | 1 | 2012 | 9 | 0.410 |
Why?
|
Algorithms | 3 | 2019 | 401 | 0.410 |
Why?
|
Odds Ratio | 4 | 2018 | 286 | 0.400 |
Why?
|
Sex Distribution | 3 | 2016 | 87 | 0.390 |
Why?
|
Exercise | 1 | 2016 | 474 | 0.390 |
Why?
|
Time Factors | 6 | 2019 | 1642 | 0.380 |
Why?
|
Chi-Square Distribution | 3 | 2018 | 148 | 0.380 |
Why?
|
Multivariate Analysis | 3 | 2018 | 332 | 0.380 |
Why?
|
Patient Positioning | 1 | 2011 | 37 | 0.380 |
Why?
|
Periodicals as Topic | 3 | 2020 | 41 | 0.370 |
Why?
|
Observational Studies as Topic | 3 | 2019 | 18 | 0.370 |
Why?
|
Positron-Emission Tomography | 4 | 2019 | 91 | 0.360 |
Why?
|
Ambulatory Care | 1 | 2010 | 78 | 0.360 |
Why?
|
Computed Tomography Angiography | 2 | 2021 | 24 | 0.350 |
Why?
|
Practice Guidelines as Topic | 5 | 2017 | 334 | 0.350 |
Why?
|
Utilization Review | 3 | 2020 | 6 | 0.350 |
Why?
|
Thallium Radioisotopes | 2 | 2019 | 6 | 0.330 |
Why?
|
Troponin | 3 | 2021 | 7 | 0.310 |
Why?
|
Acute Disease | 3 | 2021 | 225 | 0.310 |
Why?
|
Radionuclide Imaging | 2 | 2020 | 55 | 0.310 |
Why?
|
Glomerular Filtration Rate | 2 | 2020 | 59 | 0.300 |
Why?
|
Stroke | 3 | 2022 | 296 | 0.300 |
Why?
|
Risk | 3 | 2020 | 216 | 0.300 |
Why?
|
Drug Administration Schedule | 3 | 2018 | 232 | 0.290 |
Why?
|
Benchmarking | 2 | 2023 | 42 | 0.270 |
Why?
|
Image Processing, Computer-Assisted | 2 | 2019 | 221 | 0.270 |
Why?
|
Feasibility Studies | 5 | 2022 | 230 | 0.270 |
Why?
|
Causality | 2 | 2016 | 53 | 0.270 |
Why?
|
Age Distribution | 2 | 2016 | 95 | 0.270 |
Why?
|
Chronic Disease | 3 | 2019 | 508 | 0.270 |
Why?
|
Propensity Score | 2 | 2016 | 34 | 0.260 |
Why?
|
Logistic Models | 2 | 2018 | 410 | 0.260 |
Why?
|
Proportional Hazards Models | 3 | 2018 | 346 | 0.260 |
Why?
|
ROC Curve | 2 | 2016 | 140 | 0.260 |
Why?
|
Illinois | 3 | 2021 | 241 | 0.260 |
Why?
|
Administration, Intravenous | 2 | 2016 | 29 | 0.250 |
Why?
|
Patient Compliance | 2 | 2017 | 165 | 0.250 |
Why?
|
Syndrome | 2 | 2023 | 89 | 0.240 |
Why?
|
Decision Making | 2 | 2017 | 227 | 0.240 |
Why?
|
Point-of-Care Systems | 2 | 2018 | 53 | 0.240 |
Why?
|
Cause of Death | 2 | 2015 | 65 | 0.230 |
Why?
|
Dyspnea | 1 | 2023 | 36 | 0.220 |
Why?
|
Placebo Effect | 2 | 2014 | 25 | 0.220 |
Why?
|
Anticoagulants | 3 | 2022 | 102 | 0.220 |
Why?
|
Hypotension | 1 | 2022 | 27 | 0.220 |
Why?
|
Pericardium | 2 | 2021 | 20 | 0.210 |
Why?
|
Journal Impact Factor | 2 | 2020 | 15 | 0.210 |
Why?
|
Pilot Projects | 3 | 2014 | 403 | 0.210 |
Why?
|
Pulmonary Veins | 1 | 2022 | 23 | 0.210 |
Why?
|
Coronary Artery Bypass | 1 | 2022 | 31 | 0.210 |
Why?
|
Ultrasonography | 2 | 2014 | 227 | 0.200 |
Why?
|
Magnetic Resonance Imaging, Cine | 1 | 2021 | 9 | 0.200 |
Why?
|
Patient Discharge | 2 | 2019 | 151 | 0.190 |
Why?
|
Technetium Tc 99m Pyrophosphate | 1 | 2020 | 1 | 0.190 |
Why?
|
Amyloid Neuropathies, Familial | 1 | 2020 | 3 | 0.190 |
Why?
|
Adipose Tissue | 1 | 2021 | 74 | 0.180 |
Why?
|
Ischemia | 1 | 2020 | 27 | 0.180 |
Why?
|
Mobile Applications | 1 | 2020 | 24 | 0.180 |
Why?
|
Electric Countershock | 1 | 2020 | 29 | 0.180 |
Why?
|
Inpatients | 2 | 2019 | 142 | 0.180 |
Why?
|
Sample Size | 1 | 2019 | 25 | 0.180 |
Why?
|
Sex Characteristics | 1 | 2021 | 135 | 0.180 |
Why?
|
Prospective Payment System | 1 | 2019 | 4 | 0.180 |
Why?
|
Ventriculography, First-Pass | 1 | 2019 | 1 | 0.180 |
Why?
|
Health Resources | 1 | 2019 | 24 | 0.170 |
Why?
|
Intermittent Pneumatic Compression Devices | 1 | 2019 | 7 | 0.170 |
Why?
|
Thrombocytopenia | 1 | 2019 | 31 | 0.170 |
Why?
|
Mitral Valve Insufficiency | 1 | 2019 | 3 | 0.170 |
Why?
|
Asymptomatic Diseases | 1 | 2019 | 18 | 0.170 |
Why?
|
Publication Bias | 1 | 2019 | 8 | 0.170 |
Why?
|
Electrodes, Implanted | 1 | 2019 | 46 | 0.170 |
Why?
|
Cardiac Resynchronization Therapy | 1 | 2019 | 21 | 0.170 |
Why?
|
Medication Adherence | 2 | 2020 | 79 | 0.170 |
Why?
|
Models, Statistical | 1 | 2019 | 133 | 0.170 |
Why?
|
Writing | 1 | 2019 | 20 | 0.170 |
Why?
|
Angioplasty, Balloon | 1 | 2019 | 19 | 0.170 |
Why?
|
Outpatients | 1 | 2019 | 54 | 0.170 |
Why?
|
Cardiac Surgical Procedures | 1 | 2019 | 43 | 0.170 |
Why?
|
Multicenter Studies as Topic | 1 | 2019 | 77 | 0.170 |
Why?
|
Antidotes | 1 | 2018 | 6 | 0.170 |
Why?
|
Hypertension, Pulmonary | 1 | 2019 | 17 | 0.170 |
Why?
|
Pericardial Window Techniques | 1 | 2018 | 3 | 0.170 |
Why?
|
Coronary Circulation | 1 | 2018 | 43 | 0.170 |
Why?
|
Pericardiocentesis | 1 | 2018 | 3 | 0.170 |
Why?
|
Plethysmography | 1 | 2018 | 4 | 0.170 |
Why?
|
Sphygmomanometers | 1 | 2018 | 3 | 0.170 |
Why?
|
Vasodilation | 1 | 2018 | 19 | 0.170 |
Why?
|
Young Adult | 2 | 2016 | 1968 | 0.170 |
Why?
|
Death | 2 | 2022 | 48 | 0.160 |
Why?
|
Heart Atria | 1 | 2019 | 72 | 0.160 |
Why?
|
Kidney | 1 | 2020 | 176 | 0.160 |
Why?
|
Angioplasty, Balloon, Coronary | 2 | 2013 | 47 | 0.160 |
Why?
|
Guidelines as Topic | 1 | 2019 | 69 | 0.160 |
Why?
|
Cardiac Pacing, Artificial | 1 | 2019 | 83 | 0.160 |
Why?
|
Respiration | 1 | 2018 | 35 | 0.160 |
Why?
|
Hospitals | 1 | 2019 | 157 | 0.160 |
Why?
|
Hospice Care | 1 | 2019 | 32 | 0.160 |
Why?
|
Hypocalcemia | 1 | 2018 | 4 | 0.160 |
Why?
|
Evidence-Based Medicine | 2 | 2014 | 213 | 0.160 |
Why?
|
Hypercalcemia | 1 | 2018 | 12 | 0.160 |
Why?
|
Tachycardia | 1 | 2018 | 51 | 0.160 |
Why?
|
Research Design | 1 | 2019 | 215 | 0.160 |
Why?
|
Angina, Stable | 1 | 2017 | 2 | 0.160 |
Why?
|
Potassium | 1 | 2018 | 68 | 0.160 |
Why?
|
Veterans | 1 | 2019 | 64 | 0.150 |
Why?
|
Chest Pain | 1 | 2017 | 24 | 0.150 |
Why?
|
Patient Readmission | 1 | 2019 | 124 | 0.150 |
Why?
|
Kidney Function Tests | 1 | 2017 | 23 | 0.150 |
Why?
|
Physician-Patient Relations | 1 | 2017 | 40 | 0.150 |
Why?
|
Central Venous Pressure | 1 | 2017 | 5 | 0.150 |
Why?
|
Palliative Care | 1 | 2019 | 149 | 0.150 |
Why?
|
Arterial Pressure | 1 | 2017 | 14 | 0.150 |
Why?
|
Patient Safety | 1 | 2017 | 50 | 0.140 |
Why?
|
Regression Analysis | 2 | 2015 | 299 | 0.140 |
Why?
|
Internship and Residency | 1 | 2020 | 213 | 0.140 |
Why?
|
Organophosphorus Compounds | 1 | 2016 | 4 | 0.140 |
Why?
|
Perfusion Imaging | 1 | 2016 | 5 | 0.140 |
Why?
|
Organotechnetium Compounds | 1 | 2016 | 7 | 0.140 |
Why?
|
Disease Management | 1 | 2017 | 123 | 0.140 |
Why?
|
Radiation Protection | 1 | 2016 | 5 | 0.140 |
Why?
|
Area Under Curve | 1 | 2016 | 67 | 0.140 |
Why?
|
Lipoprotein(a) | 1 | 2016 | 5 | 0.140 |
Why?
|
Directive Counseling | 1 | 2016 | 12 | 0.140 |
Why?
|
Hospitals, High-Volume | 1 | 2015 | 6 | 0.130 |
Why?
|
Dyslipidemias | 1 | 2016 | 23 | 0.130 |
Why?
|
Heart Rate Determination | 1 | 2015 | 1 | 0.130 |
Why?
|
Sympathetic Nervous System | 1 | 2015 | 9 | 0.130 |
Why?
|
Sex Factors | 2 | 2016 | 498 | 0.130 |
Why?
|
Workload | 1 | 2015 | 34 | 0.130 |
Why?
|
Single-Blind Method | 1 | 2015 | 120 | 0.130 |
Why?
|
Diagnostic Errors | 1 | 2015 | 40 | 0.130 |
Why?
|
Pattern Recognition, Automated | 1 | 2015 | 9 | 0.130 |
Why?
|
Rest | 1 | 2015 | 33 | 0.130 |
Why?
|
Age Factors | 2 | 2018 | 854 | 0.130 |
Why?
|
Health Services Misuse | 1 | 2015 | 3 | 0.130 |
Why?
|
Self Care | 1 | 2016 | 90 | 0.130 |
Why?
|
Self Report | 1 | 2016 | 221 | 0.120 |
Why?
|
Computer Communication Networks | 1 | 2014 | 4 | 0.120 |
Why?
|
Robotics | 1 | 2014 | 10 | 0.120 |
Why?
|
Remote Consultation | 1 | 2014 | 11 | 0.120 |
Why?
|
Population Groups | 1 | 2014 | 5 | 0.120 |
Why?
|
Surgeons | 1 | 2015 | 76 | 0.120 |
Why?
|
Gastrointestinal Tract | 1 | 2014 | 56 | 0.120 |
Why?
|
Cost-Benefit Analysis | 1 | 2015 | 143 | 0.120 |
Why?
|
Practice Patterns, Physicians' | 1 | 2015 | 129 | 0.120 |
Why?
|
Dilatation | 1 | 2013 | 9 | 0.110 |
Why?
|
Disease-Free Survival | 1 | 2013 | 191 | 0.110 |
Why?
|
Infusions, Intravenous | 1 | 2012 | 78 | 0.110 |
Why?
|
Network Meta-Analysis | 2 | 2022 | 22 | 0.110 |
Why?
|
Drug-Related Side Effects and Adverse Reactions | 1 | 2012 | 32 | 0.110 |
Why?
|
Adenosine A2 Receptor Antagonists | 1 | 2012 | 1 | 0.100 |
Why?
|
Premedication | 1 | 2012 | 4 | 0.100 |
Why?
|
Injections, Intravenous | 1 | 2012 | 58 | 0.100 |
Why?
|
Drug Interactions | 1 | 2012 | 68 | 0.100 |
Why?
|
Diagnosis, Differential | 1 | 2013 | 399 | 0.100 |
Why?
|
Asthma | 1 | 2014 | 137 | 0.100 |
Why?
|
Supine Position | 1 | 2011 | 15 | 0.100 |
Why?
|
Safety | 1 | 2010 | 49 | 0.090 |
Why?
|
Diastole | 1 | 2010 | 36 | 0.090 |
Why?
|
Child | 1 | 2014 | 1379 | 0.090 |
Why?
|
Hemorrhage | 2 | 2022 | 75 | 0.090 |
Why?
|
Administration, Oral | 2 | 2022 | 144 | 0.090 |
Why?
|
Internet | 2 | 2020 | 90 | 0.080 |
Why?
|
Body Mass Index | 1 | 2011 | 425 | 0.080 |
Why?
|
Aging | 1 | 2018 | 1630 | 0.080 |
Why?
|
Adolescent | 1 | 2014 | 2335 | 0.080 |
Why?
|
Diabetes Mellitus, Type 2 | 1 | 2010 | 202 | 0.070 |
Why?
|
Equipment Design | 2 | 2019 | 185 | 0.070 |
Why?
|
Magnetic Resonance Imaging | 2 | 2019 | 1247 | 0.060 |
Why?
|
Receptors, Angiotensin | 1 | 2022 | 2 | 0.050 |
Why?
|
Equipment Failure | 1 | 2023 | 52 | 0.050 |
Why?
|
Neprilysin | 1 | 2022 | 9 | 0.050 |
Why?
|
Angiotensin Receptor Antagonists | 1 | 2022 | 9 | 0.050 |
Why?
|
Lasers | 1 | 2022 | 16 | 0.050 |
Why?
|
Bayes Theorem | 1 | 2022 | 39 | 0.050 |
Why?
|
Angiotensin-Converting Enzyme Inhibitors | 1 | 2022 | 27 | 0.050 |
Why?
|
Hematologic Agents | 1 | 2002 | 3 | 0.050 |
Why?
|
Vitamin K | 1 | 2022 | 8 | 0.050 |
Why?
|
Drug Therapy, Combination | 1 | 2022 | 247 | 0.050 |
Why?
|
Fibrinolytic Agents | 1 | 2022 | 58 | 0.050 |
Why?
|
Peptide Fragments | 1 | 2021 | 99 | 0.050 |
Why?
|
Clinical Decision-Making | 1 | 2020 | 38 | 0.040 |
Why?
|
Lost to Follow-Up | 1 | 2019 | 1 | 0.040 |
Why?
|
Bias | 1 | 2019 | 34 | 0.040 |
Why?
|
Fellowships and Scholarships | 1 | 2020 | 43 | 0.040 |
Why?
|
Data Interpretation, Statistical | 1 | 2019 | 98 | 0.040 |
Why?
|
Data Accuracy | 1 | 2019 | 2 | 0.040 |
Why?
|
Peer Review, Research | 1 | 2019 | 9 | 0.040 |
Why?
|
Editorial Policies | 1 | 2019 | 7 | 0.040 |
Why?
|
Authorship | 1 | 2019 | 16 | 0.040 |
Why?
|
Endpoint Determination | 1 | 2019 | 28 | 0.040 |
Why?
|
Quality Control | 1 | 2019 | 45 | 0.040 |
Why?
|
Cardiovascular Agents | 1 | 2019 | 29 | 0.040 |
Why?
|
American Heart Association | 1 | 2019 | 29 | 0.040 |
Why?
|
Bibliometrics | 1 | 2019 | 24 | 0.040 |
Why?
|
Hospital Costs | 1 | 2019 | 68 | 0.040 |
Why?
|
Checklist | 1 | 2019 | 36 | 0.040 |
Why?
|
Congresses as Topic | 1 | 2019 | 33 | 0.040 |
Why?
|
Veterans Health | 1 | 2018 | 1 | 0.040 |
Why?
|
United States Department of Veterans Affairs | 1 | 2018 | 7 | 0.040 |
Why?
|
Protective Factors | 1 | 2018 | 17 | 0.040 |
Why?
|
Software | 1 | 2018 | 72 | 0.040 |
Why?
|
Intensive Care Units | 1 | 2021 | 313 | 0.040 |
Why?
|
Databases, Factual | 1 | 2019 | 332 | 0.040 |
Why?
|
Research Report | 1 | 2017 | 7 | 0.040 |
Why?
|
Length of Stay | 1 | 2019 | 320 | 0.040 |
Why?
|
Rivaroxaban | 1 | 2016 | 8 | 0.040 |
Why?
|
Dabigatran | 1 | 2016 | 7 | 0.040 |
Why?
|
Pyridones | 1 | 2016 | 14 | 0.040 |
Why?
|
Thiazoles | 1 | 2016 | 35 | 0.040 |
Why?
|
Pyridines | 1 | 2016 | 45 | 0.040 |
Why?
|
Mortality | 1 | 2017 | 86 | 0.040 |
Why?
|
Warfarin | 1 | 2016 | 38 | 0.030 |
Why?
|
Socioeconomic Factors | 1 | 2017 | 329 | 0.030 |
Why?
|
Georgia | 1 | 2016 | 12 | 0.030 |
Why?
|
Cholesterol, LDL | 1 | 2016 | 33 | 0.030 |
Why?
|
Current Procedural Terminology | 1 | 2015 | 13 | 0.030 |
Why?
|
MEDLINE | 1 | 2015 | 5 | 0.030 |
Why?
|
Up-Regulation | 1 | 2016 | 174 | 0.030 |
Why?
|
Germany | 1 | 2014 | 10 | 0.030 |
Why?
|
Learning Curve | 1 | 2014 | 18 | 0.030 |
Why?
|
Tomography, X-Ray Computed | 1 | 2019 | 777 | 0.030 |
Why?
|
Phantoms, Imaging | 1 | 2014 | 42 | 0.030 |
Why?
|
Materials Testing | 1 | 2014 | 136 | 0.030 |
Why?
|
Longitudinal Studies | 1 | 2018 | 1462 | 0.030 |
Why?
|
Postoperative Complications | 1 | 2019 | 957 | 0.030 |
Why?
|
Clinical Competence | 1 | 2014 | 230 | 0.030 |
Why?
|
Intra-Abdominal Fat | 1 | 2010 | 42 | 0.020 |
Why?
|
Hypertension | 1 | 2010 | 273 | 0.020 |
Why?
|
Motor Activity | 1 | 2010 | 372 | 0.020 |
Why?
|